micro-community-banner
 
  • Saved
Collaborating with Pharmacists to Improve Patient Outcomes

HCP and Pharm

In the current landscape of the American medical system, the growing complexity of patient care demands a collaborative approach where the diverse expertise of healthcare professionals converges to enhance patient outcomes. Among these collaborations, the partnership between physicians, other prescribers, and pharmacists stands out as a critical factor in delivering high-quality, comprehensive care.

For patients, this collaboration translates into better health outcomes through comprehensive treatment plans that address their needs from multiple angles. In many community pharmacy settings, a pharmacist serves as a very accessible healthcare provider—anyone can go to the pharmacy counter and ask about recommendations for over-the-counter treatments or medical advice without needing to make an appointment.

Pharmacological treatment is a cornerstone of patient care, and optimal outcomes are often contingent on the proper selection, dosing, and monitoring of medications. By collaborating with pharmacists, physicians and prescribers can leverage the complementary knowledge and experience of these medication experts to ensure that treatment goals are met. This interprofessional cooperation not only enhances the quality of care but also has the potential to reduce treatment costs, making healthcare more accessible and efficient.

Challenges and Barriers to Collaboration

Despite the clear benefits, there are significant barriers to effective collaboration between physicians and pharmacists. Legal and systemic challenges often hinder the development of a seamless partnership. Differing perspectives on roles, unclear divisions of responsibilities, and financial constraints are just a few of the obstacles that must be addressed to unlock the full potential of this collaboration.

The COVID-19 pandemic, however, has shown that these challenges can be overcome. During the pandemic, the role of pharmacists expanded significantly, often out of necessity. Pharmacists took on greater responsibilities in patient care, working closely with physicians to manage treatment plans, ensure medication safety, and provide critical support during a time of unprecedented strain on the healthcare system. Helping to provide medical consultations and vaccines during the pandemic when many providers were operating on a virtual basis helped to bridge a gap in access to care. This experience highlighted the value of pharmacist involvement and emphasized the need for ongoing teamwork between healthcare providers.

Moving Forward: The Future of Physician-Pharmacist Collaboration

The future of healthcare depends on building and nurturing multidisciplinary partnerships. By doing so, the healthcare team can improve outcomes, reduce the risk of medication-related issues, and contribute to a more efficient healthcare system.

By addressing the legal and systemic barriers, clarifying roles and responsibilities, and fostering a culture of mutual respect and communication, the medical community can create a more integrated and effective care model. As we move forward, it is crucial to continue refining and expanding this partnership, ensuring that all healthcare providers work together to achieve the best possible outcomes for their patients.

What are the key benefits of collaboration between healthcare providers, such as physicians, pharmacists, and other prescribers, in improving patient outcomes?

What are the most significant barriers to interprofessional collaboration in healthcare, and how can these be overcome?

  • Saved
Current Position of Gliclazide and Sulfonylureas in the Contemporary Treatment Paradigm for Type 2 Diabetes: A Scoping Review - PubMed

Current Position of Gliclazide and Sulfonylureas in the Contemporary Treatment Paradigm for Type 2 Diabetes: A Scoping Review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38935188/

The increasing burden of type 2 diabetes (T2D), in relation to alarming rise in the prevalence; challenges in the diagnosis, prevention, and treatment; as well as the substantial impact of...

Gliclazide modified release (MR) offers effective glycemic control with a low hypoglycemia risk, supporting its essential role in managing type 2 diabetes, particularly in specific populations and treatment strategies.

  • Saved
Warning of severe pulmonary embolism after cerebral angiography: A case report and literature review - PubMed

Warning of severe pulmonary embolism after cerebral angiography: A case report and literature review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39331922/

PE is a rare complication of cerebral angiography, but the fatality rate is very high. Neurologists must not only early identify and effectively treat this complication, but more importantly, pay...

Acute pulmonary embolism, though rare after cerebral angiography, can be fatal. Neurologists should prioritize its prevention, early identification, and effective treatment to mitigate risks and improve patient outcomes.

  • Saved

Prescribing Information and Medication Guide

Desktop imageMobile image
Expand +

INDICATION AND LIMITATIONS OF USE

TRADJENTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

TRADJENTA is not recommended in patients with type 1 diabetes mellitus.

TRADJENTA has not been studied in patients with a history of pancreatitis, and it is unknown if using TRADJENTA increases the risk of developing pancreatitis in these patients.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: Hypersensitivity to linagliptin or any of the excipients in TRADJENTA, reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred.

WARNINGS AND PRECAUTIONS

Pancreatitis: Acute pancreatitis, including fatal pancreatitis, has been reported in patients taking TRADJENTA. Take careful notice of potential signs and symptoms of pancreatitis and, if suspected, promptly discontinue and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using TRADJENTA.

Hypoglycemia: The use in combination with insulin or insulin secretagogues increases the risk of hypoglycemia. A lower dosage of insulin or insulin secretagogue may be required.

Hypersensitivity Reactions: Discontinue TRADJENTA, assess for other potential causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes mellitus. Use caution in a patient with a history of angioedema to another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with TRADJENTA.

Severe and Disabling Arthralgia: Severe and disabling arthralgia has been reported in patients taking TRADJENTA. Consider TRADJENTA as a possible cause for severe joint pain and/or disabling arthralgia and discontinue, if appropriate.

Bullous Pemphigoid: There have been reports of bullous pemphigoid requiring hospitalization. Tell patients to report development of blisters or erosions. If bullous pemphigoid is suspected, discontinue TRADJENTA.

Heart Failure: Heart failure has been observed with two other members of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Consider the risks and benefits of TRADJENTA in patients at risk for heart failure, such as those with a prior history of heart failure and a history of renal impairment. Monitor patients for signs and symptoms. Advise patients of the symptoms of heart failure and to immediately report such symptoms. If heart failure develops consider discontinuation of TRADJENTA.

MOST COMMON ADVERSE REACTIONS (≥5%): Nasopharyngitis, hypoglycemia (when used in combination with sulfonylurea)

DRUG INTERACTIONS: The efficacy of TRADJENTA may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. Alternative treatments should be used.

USE IN SPECIFIC POPULATIONS: Use during pregnancy only if clearly needed. Exercise caution when administering to a nursing woman.

CL-TJ-100060 06.16.2023

References:

  1. TRADJENTA Prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc.
  2. JANUVIA Prescribing Information. Merck & Co., Inc.

Abbreviations

DPP-4i: dipeptidyl peptidase-4 inhibitor; eGFR: estimated glomerular filtration rate; T2DM: type 2 diabetes mellitus

Copyright © 2024 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved. [09/24] PC-US-137949

  • Saved
Background Image DesktopBackground Image Mobile

Selenium (Se) plays a dual role in diabetes, with potential risks for men and benefits for women, especially in gestational diabetes. High Se status may improve outcomes in type 2 diabetes, including lowering cardiovascular risks. Precision in Se intake and management is key for patient care.

Read More